Advertisement

Early Warning Systems and Oncological Critical Care Units

  • Michelle O’MahonyEmail author
  • Tim Wigmore
Reference work entry

Abstract

In the late twentieth century, it was increasingly recognized that up to three-quarters of all patients who suffer an inhospital cardiac arrest and/or require rescue transfer to a higher level of care have worsening physiological parameters in the antecedent hours prior to critical demise. This recognition highlighted the need for early identification of these patients to facilitate timely intervention and provide the appropriate language for escalation of care. Subsequent development and implementation of early warning systems became a global healthcare initiative, and while there are multiple derivations, the vast majority of hospitals now utilize some form of track and trigger system to facilitate early identification of patients at risk of clinical demise.

Oncology patients are at risk of clinical deterioration due to the neoplastic state, complications of antitumor therapies, and noncancer-related comorbidities. Early identification of at-risk oncology patients would prove particularly beneficial to facilitate early and appropriate discussions for treatment goals, ceilings of care, and multidisciplinary team input. At present, generic early warning systems have not been validated in this population and fail to account for a persistent deranged physiology which may represent a new baseline in these patients.

In this chapter we discuss the fundamental principles of early warning systems and their position within modern medicine, their strengths and limitations, the associated infrastructures, and the particular challenges facing early warning systems in oncological patients.

Keywords

Early warning systems Rapid response teams Track and trigger 

References

  1. 1.
    Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11(7):e0160221.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    National Institute for Health and Care Excellence. Acutely ill patients in hospital. Recognition of and response to acute illness in adults in hospital. NICE Clinical Guidelines, No. 50. 2007; https://www.nice.org.uk/Guidance/CG50.
  3. 3.
    Agulnik A, Forbes PW, Stenquist N, Rodriguez-Galindo C, Kleinman M. Validation of a pediatric early warning score in hospitalised pediatric oncology and hematopoietic stem cell transplant patients. Pediatr Crit Care Med. 2016;17:e146–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Akre M, Finkelstein M, Erickson M, Liu M, Vanderbilt L, Billman G. Sensitivity of the pediatric early warning score to identify patient deterioration. Pediatrics. 2010;215:2763–9.Google Scholar
  5. 5.
    Bach S, Kessler I, Heron P. Nursing a grievance? The role of healthcare assistants in a modernized national health service. Gender Work Organ. 2009;19(2).  https://doi.org/10.1111/j.1468-0432.2009.00502.x.CrossRefGoogle Scholar
  6. 6.
    Bailey TC, Chen Y, Mao Y, Lu C, Hackmann G, Micek ST, Heard KM, Faulkner KM, Kollef MH. A trial of a real-time alert for clinical deterioration in patients hospitalized on general medical wards. J Hosp Med. 2013;8:236–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Bell D, Mac A, Ochoa Y, Gordon M, Gregurich MA, Taylor T. The Texas Children’s Hospital Pediatric Advanced Warning Score as a predictor of clinical deterioration in hospitalized infants and children: a modification of the PEWS tool. J Pediatr Nurs. 2013;28:e2–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Bonafide CP, Localio AR, Song L, Roberts KE, Nadkarni VM, Priestley M, Paine CW, Zander M, Lutts M, Brady PW, Keren R. Cost-benefit analysis of a medical emergency team in a children’s hospital. Pediatrics. 2014;134(2):235–41.PubMedCrossRefGoogle Scholar
  9. 9.
    Chua W, See M, Legio-Quigley H, Jones D, Tee A, Liaw S. Factors influencing the activation of the rapid response system for clinically deteriorating patients by frontline ward clinicians: a systematic review. Int J Qual Health Care. 2017;29(8):981–98.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Comis RL, Kuppinger MS, Ginsberg SJ, Crooke ST, Gilbert R, Auchincloss JH, Prestayko AW. Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res. 1979;39:5076–80.PubMedGoogle Scholar
  11. 11.
    Confidential Enquiry into Maternal and Child Health (CEMACH). Why children die – a pilot study 2006. London: CEMACH; 2008.Google Scholar
  12. 12.
    Cooksley T, Kitlowski E, Haji-Michael P. Effectiveness of Modified Early Warning Score in predicting outcomes in oncology patients. Qjm Int J Med. 2012;105(11):1083–8.CrossRefGoogle Scholar
  13. 13.
    Douglas C, Osborne S, Windsor C, Fox R, Booker C, Jones L, Gardner G. Nursing and medical perceptions of a hospital rapid response system: new process but same old game? J Nurs Care Qual. 2016;31:E1–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47:765–79.PubMedCrossRefGoogle Scholar
  15. 15.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok J, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845–55.  https://doi.org/10.1056/NEJMoa1611299.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346–53.  https://doi.org/10.1001/jamaoncol.2016.1051.CrossRefGoogle Scholar
  17. 17.
    Green AL, Williams A. An evaluation of an early warning clinical marker referral tool. Intensive Crit Care Nurs. 2006;22:274–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Gill MR, Reiley DG, Green SM. Interrater reliability of Glasgow Coma Scale scores in the emergency department. Ann Emerg Med. 2004;43(2):215–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Guazzi M, Polese A, Magrini F, Fiorentini C, Olivari MT. Negative influences of ascites on the cardiac function of cirrhotic patients. Am J Med. 1975;59(2):165–70.PubMedCrossRefGoogle Scholar
  20. 20.
    Gutierrez C, McEvoy C, Mead E, Stephens RS, Munshi L, Detsky ME, Pastores SM, Nates JL. Management of the critically ill adult chimeric antigen receptor-T cell therapy patient: a critical care perspective. Crit Care Med. 2018;  https://doi.org/10.1097/CCM.0000000000003258. [Epub ahead of print]PubMedCrossRefGoogle Scholar
  21. 21.
    Haegdorens F, Van Bogaert P, Roelant E, De Meester K, Misselyn M, Wouters K, Monsieurs KG. The introduction of a rapid response system in acute hospitals: a pragmatic stepped wedge cluster randomised controlled trial. Resuscitation. 2018;129:127–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Haines C, Perrott M, Weir P. Promoting care for acutely ill children—development and evaluation of a paediatric early warning tool. Intensive Crit Care Nurs. 2006;22:73–81.  https://doi.org/10.1016/j.iccn.2005.09.PubMedCrossRefGoogle Scholar
  23. 23.
    Haugnes H, Oldenburg J, Bremnes R. Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urol Oncol. 2015;33(9):399–406.PubMedCrossRefGoogle Scholar
  24. 24.
    Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer: a randomised controlled trial. Lancet. 2016;387:1540–50.  https://doi.org/10.1016/S0140-6736(15)01281-7.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Hillman KM, Bristow PJ, Chey T, Daffurn K, Jacques T, Norman SL, Bishop GF, Simmons G. Duration of life-threatening antecedents prior to intensive care admission. Intensive Care Med. 2002;28:1629–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Horan PG, McMullin MF, McKeown PP. Anthracycline cardiotoxicity. Eur Heart J. 2006;27(10):1137–8. Epub 2006 Apr 12PubMedCrossRefGoogle Scholar
  27. 27.
    Kause J, Smith G, Prytherch D, Parr M, Flabouris A, Hillman K, Intensive Care Society (UK), Australian and New Zealand Intensive Care Society Clinical Trials Group. A comparison of antecedents to cardiac arrests, deaths and emergency intensive care admissions in Australia and New Zealand, and the United Kingdom – the ACADEMIA study. Resuscitation. 2004;62:275–82.PubMedCrossRefGoogle Scholar
  28. 28.
    Kellett J, Kim A. Validation of an abbreviated VitalPAC™ Early Warning Score (ViEWS) in 75,419 consecutive admissions to a Canadian regional hospital. Resuscitation. 2012;83:297–302.PubMedCrossRefGoogle Scholar
  29. 29.
    Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Lambert V, Matthews A, MacDonell R, Fitzsimons J. Paediatric early warning systems for detecting and responding to clinical deterioration in children: a systematic review. BMJ Open. 2017;7:e014497.  https://doi.org/10.1136/bmjopen-2016-014497.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293–306.PubMedCrossRefGoogle Scholar
  33. 33.
    Mackintosh N, Humphrey C, Sandall J. The habitus of ‘rescue’ and its significance for implementation of rapid response systems in acute health care. Soc Sci Med. 2014;120:233–42.PubMedCrossRefGoogle Scholar
  34. 34.
    Mackintosh N, Sandall J. Overcoming gendered and professional hierarchies in order to facilitate escalation of care in emergency situations: the role of standardised communication protocols. Soc Sci Med. 2010;71:1683–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Magee MS, Snook AE. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. Discov Med. 2014;18(100):265–71.PubMedGoogle Scholar
  36. 36.
    Maharaj R, Stelfox HT. Rapid response teams improve outcomes: no. Intensive Care Med. 2016;42:596–8.PubMedCrossRefGoogle Scholar
  37. 37.
    McCorkle R, Ercolano E, Lazenby M, Schulman-Green D, Schilling LS, Lorig K, Wagner EH. Self-management: enabling and empowering patients living with cancer as a chronic illness. CA Cancer J Clin. 2011;61(1):50–62.  https://doi.org/10.3322/caac.20093.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368–76.PubMedCrossRefGoogle Scholar
  39. 39.
    MERIT study investigators. Introduction of the medical emergency team (MET) system: a cluster-randomised controlled trial. Lancet. 2005;365(9477):2091–7.CrossRefGoogle Scholar
  40. 40.
    Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–89.CrossRefGoogle Scholar
  41. 41.
    Moon A, Cosgrove JF, Lea D, Fairs A, Cressey DM. An eight year audit before and after the introduction of modified early warning score (MEWS) charts, of patients admitted to a tertiary referral intensive care unit after CPR. Resuscitation. 2011;82:150–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Morgan RJM, Williams F, Wright MM. An early warning scoring system for detecting developing critical illness. Clin Intensive Care. 1997;8:100.Google Scholar
  43. 43.
    Naoum FA. Iron deficiency in cancer patients. Rev Bras Hematol Hemoter. 2016;38(4):325–30.  https://doi.org/10.1016/j.bjhh.2016.05.009.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Nielsen LG, Folkestad L, Brodersen JB, Brabrand M. Inter-observer agreement in measuring respiratory rate. PLoS One. 2015;10(6):E0129493.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prové A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82(2):291–4.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Philip K, Richardson R, Cohen M. Staff perceptions of respiratory rate measurement in a general hospital. Br J Nurs. 2013;22(10):570–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Prytherch DR, Smith GB, Schmidt PE, Featherstone PI. ViEWS – towards a national early warning score for detecting adult inpatient deterioration. Resuscitation. 2010;81:932–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.  https://doi.org/10.1056/NEJMoa1412082.PubMedCrossRefGoogle Scholar
  49. 49.
    Rothschild JM, Gandara E, Woolf S, Williams DH, Bates DW. Single-parameter early warning criteria to predict life-threatening adverse events. J Patient Saf. 2010;6:97–101.PubMedCrossRefGoogle Scholar
  50. 50.
    Royal College of Physicians. National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS, Updated report of a working party. London: RCP; 2017.Google Scholar
  51. 51.
    Sandroni C, Cavallaro F. Failure of the afferent limb: a persistent problem in rapid response systems. Resuscitation. 2011;82:797–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin toxicity in the west of Scotland 1991–1995: a review of patients with germ cell tumours. Br J Cancer. 1998;78:1061–6.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Smith GB, Prytherch DR, Meredith P, Schmidt PE, Featherstone PI. The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death. Resuscitation. 2013;8(4):465–70.CrossRefGoogle Scholar
  54. 54.
    Trinkle RM, Flabouris A. Documenting Rapid Response System afferent limb failure and associated patient outcomes. Resuscitation. 2011;82(7):810–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Vincent F, Soares M, Mokart D, Lemiale V, Bruneel F, Boubaya M, Gonzalez F, Cohen Y, Azoulay E, Darmon M. In-hospital and day-120 survival of critically ill solid cancer patients after discharge of the intensive care units: results of a retrospective multicenter study – a Groupe de recherche respiratoire en réanimation en Onco–Hématologie (Grrr-OH) study. Ann Intensive Care. 2018;8(1):1–8.CrossRefGoogle Scholar
  56. 56.
    Wendon J, Hodgson C, Bellomo R. Rapid response teams improve outcomes: we are not sure. Intensive Care Med. 2016;42:599–601.PubMedCrossRefGoogle Scholar
  57. 57.
    Wigmore T, Farquhar-Smith P. Outcomes for critically ill cancer patients in the ICU: current trends and prediction. Int Anesthesiol Clin. 2016;54:e62–75.PubMedCrossRefGoogle Scholar
  58. 58.
    Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer. 2005;13(11):870–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Anaesthesia, Critical Care and Pain MedicineRoyal Marsden HospitalLondonUK

Personalised recommendations